Coiled Therapeutics has enrolled six patients in a trial testing a reformulated softgel version of its cancer drug AO-252, designed to improve absorption compared to the earlier tablet form. Shore Capital supports the progress and highlights the potential value of upcoming safety data expected by the end of 2026 and preliminary efficacy results in early 2027. The drug targets the TACC3 protein, which promotes tumor growth but is less critical to healthy cells, suggesting a chance for effective cancer treatment with fewer side effects. AO-252 has already demonstrated an 80% clinical benefit rate in a small group of heavily pre-treated patients, marking it as a promising candidate for further development and partnerships.
Coiled Therapeutics' cancer drug AO-252 trial progress is noted alongside Pluang's Health-sector market data. For readers following Health-sector stocks, here is Pluang's market snapshot as of Sep 21, 2026 20:01 WIB: Of 95 priced US Health-sector stocks, 56 rose and 25 fell. Notable movers include OSCR at USD 31.35 with a -2.43% change and a typical hold time of 14 days, ABEO at USD 5.46 with a -1.97% change and a 22-day hold time, and TXG at USD 78.08 with a +1.93% change and a 94-day hold time.
Morgan Stanley upgraded NNN REIT from Neutral to Overweight due to its stable income and strong financial health. The REIT boasts a 99.1% occupancy rate and 97.5% fixed-rate debt, ensuring steady rental income and protection against interest rate hik...
On September 21, 2026, Sandisk was added to the S&P 100 index, replacing Nike, which was removed on the same day. This change reflects shifts in market capitalization and company performance within the index. The update is significant for investors t...
Several top analysts, including Cantor Fitzgerald, Guggenheim, Morgan Stanley, and BTIG Research, have raised price targets and upgraded their outlooks for ServiceNow, signaling confidence in the company's long-term growth. Despite this, the stock ha...
Piper Sandler lowered Colgate-Palmolive's price target to $95 due to weak North American demand and rising competition. The company is responding by focusing on premium oral care innovations, expanding the Fabuloso line, increasing advertising, and c...
MillerKnoll is set to report Q3 2026 earnings with analysts expecting $0.35 EPS and $940.93 million in revenue. The North America Contract segment shows strength with higher prices and volumes, while the Global Retail segment struggles due to tariffs...
